All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD47×TAZ dual chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD47 and TAZ. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD47 antibody linked to CD28, 4-1BB (CD137) and CD3ζ signaling domains, and another lentiviral vector expressing scFv of anti-TAZ antibody linked to TET2. The incorporation of TET2 domain enables inhibition of IL-6 expression and prevents the cytokine storm. The vector product was designed for the treatment of breast cancer.
CAR Construction : Fig.1 Affinity determination of 5F9. Binding of 5F9 to monomeric CD47 was analyzed by surface plasmon resonance yielding the indicated traces and binding constants. Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., ... & Majeti, R. (2015). Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PloS one, 10(9), e0137345. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD47×TAZ h(CD28-41BB-CD3ζ, TET2) Dual CAR, pCDCAR1 (CAR-LC364). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION